Navigation Links
Commercial future for Model Gut
Date:2/26/2013

The Dynamic Gastric Model, developed from years of research at the Institute of Food Research, has taken significant steps towards improving its commercial use by food and drug companies worldwide.

IFR and the technology management company Plant Bioscience Limited (PBL) have secured funding from the Biotechnology and Biological Sciences Research Council (BBSRC) to further develop the Dynamic Gastric Model to validate and improve how well it simulates the release of nutrients or drugs in humans.

PBL has also signed an exclusive license agreement with Bioneer regarding use of the Dynamic Gastric Model (DGM). Bioneer has also acquired PBL's highly successful DGM contract research business (www.modelgut.com) which provides specialist DGM services to the pharmaceutical and food-related industries.

The DGM is based on 15 years of research at the Institute of Food Research, in partnership with PBL. It accurately simulates the physical and biochemical processes that occur within the human stomach. It is the world's first computer controlled, mechanical simulator of gastric digestion that works in real-time to process real chewed foods or meals and oral pharmaceutical or nutraceutical products.

The commercialisation of the model represents a significant achievement for IFR in developing research and making it commercially viable. It is an example of IFR's commitment to the translation of our science for the benefit of society and commerce.

IFR will continue to work with the DGM, as part of its core research into understanding the complex interaction between health, the food we eat and our gut. The new two-year project, with funding from the BBSRC's Super Follow on Fund scheme, is worth over 900k and will refine and improve models to ensure that IFR can continue its strategic research to determine how the nutritional quality and health benefits of the food we eat can be influenced by the way it is digested. This research at IFR in the future will continue to utilise the in vitro models which have been developed here including the DGM and the model colon.

The model will also be further developed to enable studies that would not be permitted in humans; for instance, the impact of taking drugs with alcohol, or the development of an infant formulation.

IFR's Professor Peter Wilde said: "We will clearly demonstrate how well the model simulates and predicts the availability of nutrients or drugs in humans, and to refine the model so that it can be more widely used, and therefore reduce the reliance on animal and human studies. This will significantly enhance the commercial and scientific potential of the model."

The license agreement for the Dynamic Gastric Model expands Bioneer's readily available services for pharmaceutical dosage form testing, drug discovery screening, bioequivalence assessment, and functional food analysis. The Model Gut services will be integrated into Bioneer's own service offering under the Bioneer:FARMA brand.

Professor Anette Mllertz, Head of Department at Bioneer:FARMA said: "The DGM takes our services to a highly advanced level. In combination with our existing digestion models, we can now conduct advanced analyses along the whole gastro-intestinal tract."

Martin Stocks, PBL Business Development Manager, said: "We are delighted to partner Bioneer:FARMA to take The Model Gut into an exciting new phase. The integration with Bioneer:FARMA will provide a wide array of complementary capabilities that will both expand and enable the unique capabilities of the Model Gut's technologies for determining the performance of ingested materials in the gastric and intestinal compartments."


'/>"/>

Contact: Andrew Chapple
andrew.chapple@ifr.ac.uk
44-016-032-51490
Norwich BioScience Institutes
Source:Eurekalert  

Related biology news :

1. Kessler Foundation implements Ekso Bionics first commercial robotic exoskeleton
2. A study confirms that long commercials evoke stronger emotions
3. Researchers take hibiscus efforts to commercialization
4. Sandia seeks commercial partners for revolutionary SpinDx medical diagnostic tool
5. NIST focuses on testing standards to support lab on a chip commercialization
6. Bed bugs are not repelled by commercial ultrasonic frequency devices
7. UC Berkeley, UCSF and Stanford join forces to help commercialize university innovations
8. The future of plant science - a technology perspective
9. The future of plant science a technology perspective
10. Is seaweed the future of biofuel?
11. Algae biofuels: the wave of the future
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Commercial future for Model Gut
(Date:6/2/2016)... 2, 2016 The Department of Transport ... the 44 million US Dollar project, for the , ... including Personalization, Enrolment, and IT Infrastructure , to ... production and implementation of Identity Management Solutions. Numerous renowned international ... Decatur was selected for the most compliant ...
(Date:6/1/2016)... YORK , June 1, 2016 ... Technology in Election Administration and Criminal Identification to Boost ... to a recently released TechSci Research report, " Global ... By Region, Competition Forecast and Opportunities, 2011 - 2021", ... 24.8 billion by 2021, on account of growing security ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the ... today the Clinical Reach Virtual Patient Encounter CONSULT module which enables both ... physician and clinical trial team. , Using the CONSULT module, patients and physicians can ...
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in ... Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio ... practical tips, tools, and strategies for clinical researchers. , “The landscape of how ...
Breaking Biology Technology: